Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) CFO Jason Haas purchased 1,000 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were acquired at an average price of $20.00 per share, for a total transaction of $20,000.00. Following the completion of the acquisition, the chief financial officer directly owned 62,908 shares of the company’s stock, valued at $1,258,160. This trade represents a 1.62% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Odyssey Therapeutics Stock Up 6.3%
Shares of Odyssey Therapeutics stock opened at $17.45 on Tuesday. Odyssey Therapeutics, Inc. has a 12 month low of $15.35 and a 12 month high of $20.30.
Featured Stories
- Five stocks we like better than Odyssey Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
